Global Pediatric Epilepsy Therapeutics Market 2019-2023

小児てんかん治療薬の世界市場2019-2023

◆タイトル:Global Pediatric Epilepsy Therapeutics Market 2019-2023
◆商品コード:IRTNTR30171
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月12日
◆ページ数:119
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、小児てんかん治療薬の世界市場について調査・分析し、市場概要、市場環境、小児てんかん治療薬市場規模、製品別(第2世代、第3世代、第1世代)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・小児てんかん治療薬の世界市場概要
・小児てんかん治療薬の世界市場環境
・小児てんかん治療薬の世界市場動向
・小児てんかん治療薬の世界市場規模
・小児てんかん治療薬の世界市場:業界構造分析
・小児てんかん治療薬の世界市場:製品別(第2世代、第3世代、第1世代)
・小児てんかん治療薬の世界市場:地域別市場規模・分析
・小児てんかん治療薬の北米市場規模・予測
・小児てんかん治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・小児てんかん治療薬のアジア太平洋市場規模・予測
・小児てんかん治療薬の主要国分析
・小児てんかん治療薬の世界市場:意思決定フレームワーク
・小児てんかん治療薬の世界市場:成長要因、課題
・小児てんかん治療薬の世界市場:競争環境
・小児てんかん治療薬の世界市場:関連企業情報(ベンダー分析)

107 pages, November 2018
About this market
The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. Technavio’s analysts have predicted that the pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.
Market Overview
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Second-generation anti-epileptics – Market size and forecast 2018-2023
• Third-generation anti-epileptics – Market size and forecast 2018-2023
• First-generation anti-epileptics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eisai
• GlaxoSmithKline
• GW Pharmaceuticals
• Pfizer
• UCB
PART 14: APPENDIX
Research methodology
List of abbreviations
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global epilepsy drugs market
Exhibit 02: Segments of global epilepsy drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Various syndromes of pediatric epilepsy
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Second-generation anti-epileptics – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Second-generation anti-epileptics – Year-over-year growth 2019-2023 (%)
Exhibit 22: Third-generation anti-epileptics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Third-generation anti-epileptics – Year-over-year growth 2019-2023 (%)
Exhibit 24: First-generation anti-epileptics – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: First-generation anti-epileptics approval timeline
Exhibit 26: First-generation anti-epileptics – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Estimated number of prescriptions for BANZEL (February 1, 2015-May 31, 2017)
Exhibit 43: Overview of late-stage molecules in pipeline
Exhibit 44: Side effects of pediatric epilepsy therapeutics
Exhibit 45: Patent expiration for few noted AEDs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Eisai – Vendor overview
Exhibit 53: Eisai – Business segments
Exhibit 54: Eisai – Organizational developments
Exhibit 55: Eisai – Segment focus
Exhibit 56: Eisai – Geographic focus
Exhibit 57: Eisai – Key offerings
Exhibit 58: Eisai – Key customers
Exhibit 59: GlaxoSmithKline – Vendor overview
Exhibit 60: GlaxoSmithKline – Business segments
Exhibit 61: GlaxoSmithKline – Organizational developments
Exhibit 62: GlaxoSmithKline – Segment focus
Exhibit 63: GlaxoSmithKline – Geographic focus
Exhibit 64: GlaxoSmithKline – Key offerings
Exhibit 65: GlaxoSmithKline – Key customers
Exhibit 66: GW Pharmaceuticals – Vendor overview
Exhibit 67: GW Pharmaceuticals – Business segments
Exhibit 68: GW Pharmaceuticals – Organizational developments
Exhibit 69: GW Pharmaceuticals – Segment focus
Exhibit 70: GW Pharmaceuticals – Geographic focus
Exhibit 71: GW Pharmaceuticals – Key offerings
Exhibit 72: GW Pharmaceuticals – Key customers
Exhibit 73: Pfizer – Vendor overview
Exhibit 74: Pfizer – Business segments
Exhibit 75: Pfizer – Organizational developments
Exhibit 76: Pfizer – Segment focus
Exhibit 77: Pfizer – Geographic focus
Exhibit 78: Pfizer – Key offerings
Exhibit 79: Pfizer – Key customers
Exhibit 80: UCB – Vendor overview
Exhibit 81: UCB – Business segments
Exhibit 82: UCB – Organizational developments
Exhibit 83: UCB – Geographic focus
Exhibit 84: UCB – Key offerings
Exhibit 85: UCB – Key customers





【掲載企業】

Eisai、GlaxoSmithKline、GW Pharmaceuticals、Pfizer、UCB

★調査レポート[小児てんかん治療薬の世界市場2019-2023] (Global Pediatric Epilepsy Therapeutics Market 2019-2023 / IRTNTR30171)販売に関する免責事項
[小児てんかん治療薬の世界市場2019-2023] (Global Pediatric Epilepsy Therapeutics Market 2019-2023 / IRTNTR30171)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆